Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

October 2017 - FRMC

Featured Article

News
10/26/2017

Dean Celia

Dean Celia
Amazon is eyeing the pharmaceutical business; Apple has the attention of a big insurer; Google’s sister company is aiming to produce data-driven interventions— but what does it all mean for payers?
Amazon is eyeing the pharmaceutical business; Apple has the attention of a big insurer; Google’s sister company is aiming to produce data-driven interventions— but what does it all mean for payers?
Amazon is eyeing the...
10/26/2017
First Report Managed Care

News

News
10/26/2017

Mary Beth Nierengarten

Mary Beth Nierengarten
Research and development in HIV treatment over the last decade has turned what was once a deadly disease into a treatable chronic condition. However, while groundbreaking new regimens are continually coming to the market in fewer daily doses,...
Research and development in HIV treatment over the last decade has turned what was once a deadly disease into a treatable chronic condition. However, while groundbreaking new regimens are continually coming to the market in fewer daily doses,...
Research and development in HIV...
10/26/2017
First Report Managed Care
News
10/26/2017

By Eileen Koutnik-Fotopoulos

By Eileen Koutnik-Fotopoulos
Some formularies are pushing patients away from cheaper generics in favor of high cost generics. We spoke with some managed care experts to understand why this practice is in place for some insurers.
Some formularies are pushing patients away from cheaper generics in favor of high cost generics. We spoke with some managed care experts to understand why this practice is in place for some insurers.
Some formularies are pushing...
10/26/2017
First Report Managed Care
News
10/26/2017

Dean Celia

Dean Celia
Amazon is eyeing the pharmaceutical business; Apple has the attention of a big insurer; Google’s sister company is aiming to produce data-driven interventions— but what does it all mean for payers?
Amazon is eyeing the pharmaceutical business; Apple has the attention of a big insurer; Google’s sister company is aiming to produce data-driven interventions— but what does it all mean for payers?
Amazon is eyeing the...
10/26/2017
First Report Managed Care

Department

Formulary Frontlines®
10/26/2017

S Russell Spjut, PharmD, clinical pharmacist of formulary management at MagellanRx Management

S Russell Spjut, PharmD, clinical pha...
S Russell Spjut, PharmD, discusses current first-line therapies and new treatment opions used to treat acute myeloid leukemia and their associated costs. 
S Russell Spjut, PharmD, discusses current first-line therapies and new treatment opions used to treat acute myeloid leukemia and their associated costs. 
S Russell Spjut, PharmD,...
10/26/2017
First Report Managed Care
Managed Care Q&A
10/26/2017

By Zachary Bessette and Julie Gould

By Zachary Bessette and Julie Gould ...
Steve Miller, MD, MBA, chief medical officer of Express Scripts, discusses how payers are going to have to become innovative in order to pay the high prices associated with gene therapy.
Steve Miller, MD, MBA, chief medical officer of Express Scripts, discusses how payers are going to have to become innovative in order to pay the high prices associated with gene therapy.
Steve Miller, MD, MBA, chief...
10/26/2017
First Report Managed Care
Conference Insider
10/25/2017
During a presentation at the 2017 Clinical Pathways Congress, Alan Balch, PhD, explained that clinical pathway development needs to do a better job at taking the patient perspective into account when providing cancer care.
During a presentation at the 2017 Clinical Pathways Congress, Alan Balch, PhD, explained that clinical pathway development needs to do a better job at taking the patient perspective into account when providing cancer care.
During a presentation at the...
10/25/2017
First Report Managed Care
Conference Insider
10/25/2017
Biosimilars occupy a huge place in the oncology treatment conversation these days. But what are they exactly, and how will they impact clinical pathways?
Biosimilars occupy a huge place in the oncology treatment conversation these days. But what are they exactly, and how will they impact clinical pathways?
Biosimilars occupy a huge place...
10/25/2017
First Report Managed Care
Conference Insider
10/25/2017
During the keynote speech at the RAPS 2017 Regulatory Convergence, Scott Gottlieb, MD, commissioner of the FDA, explained that the agency is focused on making drug development more efficient and cheaper in order to expedite approvals and...
During the keynote speech at the RAPS 2017 Regulatory Convergence, Scott Gottlieb, MD, commissioner of the FDA, explained that the agency is focused on making drug development more efficient and cheaper in order to expedite approvals and...
During the keynote speech at the...
10/25/2017
First Report Managed Care
Conference Insider
10/25/2017
Researcher presented at the European Association for the Study of Diabetes 2017 (EASD) in Lisbon, Portugal, highlighted the significant risk of death caused by hypoglycemia among patients with diabetes.
Researcher presented at the European Association for the Study of Diabetes 2017 (EASD) in Lisbon, Portugal, highlighted the significant risk of death caused by hypoglycemia among patients with diabetes.
Researcher presented at the...
10/25/2017
First Report Managed Care
Conference Insider
10/25/2017
In order for biosimilars to relieve the impact of high cost specialty pharmacy drugs, more uptake and education is need for patients, providers, and payers, according to a presentation at the National Association of Specialty Pharmacy Annual...
In order for biosimilars to relieve the impact of high cost specialty pharmacy drugs, more uptake and education is need for patients, providers, and payers, according to a presentation at the National Association of Specialty Pharmacy Annual...
In order for biosimilars to...
10/25/2017
First Report Managed Care

Advertisement

Advertisement

Advertisement